Adult-Onset Bleeding and Clotting Disorders: A Clinical Approach to Diagnosis and Differentiation

Dr Neeraj Manikath , claude.ai

Abstract

Adult-onset hemostatic disorders present diagnostic challenges that require systematic clinical evaluation. This review provides a practical framework for distinguishing bleeding from clotting disorders in adults, emphasizing clinical pearls, diagnostic pitfalls, and evidence-based approaches for internists managing these complex patients.

Introduction

Hemostatic disorders in adults differ fundamentally from pediatric presentations, often reflecting acquired pathology rather than inherited defects. The internist must distinguish between bleeding diatheses, thrombophilia, and the increasingly recognized paradoxical states where both coexist. Approximately 1-2% of adults will experience a significant hemostatic disorder during their lifetime, with increasing prevalence in aging populations and those with chronic diseases.

Clinical Assessment: The Foundation

History Taking: Beyond the Obvious

The bleeding history requires forensic detail. Inquire about:

Pearl #1: Ask about dental extractions specifically. A patient who underwent multiple dental procedures without excessive bleeding likely does not have a severe inherited bleeding disorder, regardless of current symptoms.

• Epistaxis: Frequency, duration (>10 minutes suggests pathology), and whether bilateral
• Menstrual history: Quantify with pictorial bleeding assessment charts (PBAC score >100 suggests menorrhagia)
• Post-surgical bleeding: Immediate versus delayed (suggests different mechanisms)
• Spontaneous versus provoked bleeding
• Joint or muscle hematomas (suggests coagulation factor deficiency)

Oyster #1: Patients often conflate easy bruising with bleeding disorders. Senile purpura and corticosteroid-induced skin fragility cause dramatic bruising without true hemostatic defects. Look for the "crocodile skin" appearance in sun-exposed areas.

For thrombotic evaluation:

• Provoked versus unprovoked thrombosis
• Arterial versus venous events (suggests different pathophysiology)
• Unusual site thrombosis (mesenteric, cerebral venous, portal—consider myeloproliferative disorders or paroxysmal nocturnal hemoglobinuria)
• Family history: Three-generation pedigree

Pearl #2: The "rule of twos" for hereditary thrombophilia: Consider testing if <2 family members with thrombosis before age 50, or >2 unprovoked events in the patient.

Physical Examination: Reading the Hemostatic Map

Physical findings provide crucial clues:

Bleeding disorders:

• Petechiae (platelet/vascular): Non-blanching, <3mm, gravity-dependent areas initially
• Purpura (platelet/vascular): 3-10mm
• Ecchymoses (coagulation factors): >10mm, often in unusual locations
• Wet purpura (oral mucosal bleeding): Suggests severe thrombocytopenia (<20,000/μL) requiring urgent intervention

Hack #1: The "tourniquet test" can be performed bedside. Inflate BP cuff to midpoint between systolic and diastolic for 5 minutes. More than 10-20 petechiae in a 5cm diameter circle suggests capillary fragility or thrombocytopenia.

Thrombotic markers:

• Superficial thrombophlebitis: Consider thrombophilia or occult malignancy (Trousseau syndrome)
• Livedoid vasculopathy: Suggests antiphospholipid syndrome
• Skin necrosis: Think warfarin-induced (protein C/S deficiency) or purpura fulminans

Pearl #3: Examine the fundi. Retinal hemorrhages in thrombocytopenia predict higher bleeding risk. Venous engorgement suggests hyperviscosity syndrome.

Laboratory Evaluation: The Strategic Approach

First-Tier Testing: The Hemostatic Screen

Order systematically, not reflexively:

1. Complete blood count with smear review: Manual review is non-negotiable
   • Platelet count and size (large platelets in immune thrombocytopenia)
   • Schistocytes suggest microangiopathic hemolytic anemia (MAHA)
   • Pseudo-thrombocytopenia from EDTA-dependent platelet clumping (affects 0.1% of samples)

Oyster #2: Always repeat a critically low platelet count in citrate tube if pseudo-thrombocytopenia suspected. This simple step prevents unnecessary treatments.

2. Prothrombin time (PT/INR): Tests extrinsic pathway (Factor VII) and common pathway

   • Prolonged in vitamin K deficiency, warfarin, liver disease, Factor VII deficiency

3. Activated partial thromboplastin time (aPTT): Tests intrinsic and common pathways

   • Prolonged in hemophilia A/B, von Willebrand disease (vWD), heparin, lupus anticoagulant

4. Fibrinogen level: Differentiates consumptive from synthetic coagulopathy

Hack #2: The "mixing study" distinguishes factor deficiency from inhibitors. Mix patient plasma 1:1 with normal plasma. If aPTT corrects, suspect deficiency. If it remains prolonged, suspect inhibitor (lupus anticoagulant or acquired hemophilia).

Bleeding Disorder Deep Dive

Von Willebrand Disease (vWD): Most common inherited bleeding disorder (1% prevalence)

Testing requires:

• Von Willebrand factor antigen (vWF:Ag)
• Von Willebrand factor activity (vWF:RCo or vWF:GPIbM)
• Factor VIII level
• Blood type (Type O individuals have 25-30% lower vWF)

Pearl #4: vWF levels fluctuate with stress, inflammation, pregnancy, and estrogen. Always test when patient is well, and repeat abnormal results. Values 30-50 IU/dL represent a "gray zone" requiring clinical correlation.

Type 1 (70-80%): Partial quantitative deficiency Type 2 (15-20%): Qualitative defects (subtypes A, B, M, N) Type 3 (<5%): Complete absence, resembles hemophilia

Platelet function disorders:

• Template bleeding time is obsolete
• PFA-100 (Platelet Function Analyzer): Screens for vWD and platelet dysfunction but has high false-positive rate
• Light transmission aggregometry: Gold standard but requires specialized lab

Hack #3: For urgent surgical patients with suspected platelet dysfunction, empiric desmopressin (DDAVP) 0.3 μg/kg can temporarily improve hemostasis while awaiting results. Effect lasts 6-12 hours.

Acquired hemophilia A: Rare (1-2 per million) but life-threatening

• Elderly patients or postpartum women with sudden severe bleeding
• Prolonged aPTT not correcting with mixing
• Low Factor VIII with positive Bethesda inhibitor assay
• Treat with bypassing agents (recombinant Factor VIIa or activated prothrombin complex concentrate) and immunosuppression

Thrombophilia Evaluation: When and What

Controversial territory: Routine thrombophilia testing rarely changes management and may harm patients through overtreatment.

Test only when results will change management:

• Age <50 with unprovoked VTE
• Recurrent VTE
• Thrombosis at unusual sites
• Strong family history
• Planning to discontinue anticoagulation

Panel includes:

• Antithrombin activity
• Protein C activity
• Protein S (free and total)
• Factor V Leiden mutation
• Prothrombin G20210A mutation
• Antiphospholipid antibodies (see below)

Oyster #3: Never test during acute thrombosis or while anticoagulated. Protein C, S, and antithrombin are consumed during clotting and suppressed by warfarin, yielding false positives. Wait 2-4 weeks off anticoagulation or use DOACs which don't affect these levels as severely.

Pearl #5: Antiphospholipid syndrome (APS) diagnosis requires both clinical criteria (thrombosis or pregnancy morbidity) AND laboratory criteria (lupus anticoagulant, anticardiolipin antibodies, or anti-β2-glycoprotein I antibodies) present on two occasions at least 12 weeks apart. Single positive tests are meaningless.

The Overlap: When Bleeding Meets Clotting

Disseminated Intravascular Coagulation (DIC):

• Simultaneous microvascular thrombosis and consumption coagulopathy
• ISTH DIC score: Platelets, PT, fibrinogen, D-dimer
• Score ≥5 indicates overt DIC

Underlying triggers (remember "STOP Making New Thrombi"):

• Sepsis (most common)
• Trauma/burns
• Obstetric complications (amniotic fluid embolism, placental abruption)
• Pancreatic disease
• Malignancy (acute promyelocytic leukemia, adenocarcinomas)
• (New) transfusion reactions
• Toxins (snake venom, drugs)

Hack #4: Serial D-dimer measurements guide DIC treatment. Rising levels despite heparin suggest worsening consumption; falling levels indicate improvement.

Thrombotic microangiopathies (TMA):

• Thrombotic thrombocytopenic purpura (TTP)
• Hemolytic uremic syndrome (HUS)
• Drug-induced (quinine, cyclosporine)

Pearl #6: The "FAT RN" mnemonic for TTP pentad (present in only 5% at diagnosis):

• Fever
• Anemia (hemolytic)
• Thrombocytopenia
• Renal dysfunction
• Neurologic changes

ADAMTS13 activity <10% confirms TTP. Don't wait for results—start plasma exchange for suspected TTP; mortality approaches 90% without treatment versus 10-20% with prompt therapy.

Clinical Algorithms: Practical Pathways

Approach to Prolonged aPTT with Bleeding

1. Repeat with mixing study
2. If corrects: Factor deficiency
   • Check Factors VIII, IX, XI
   • Check vWF panel
3. If doesn't correct: Inhibitor
   • Lupus anticoagulant (usually no bleeding)
   • Specific factor inhibitor (Bethesda assay)

Approach to Prolonged aPTT without Bleeding

1. Lupus anticoagulant most likely
2. Confirm with:
   • Dilute Russell viper venom time (dRVVT)
   • Hexagonal phase phospholipid neutralization
3. If negative, consider Factor XII deficiency (no clinical bleeding)

Oyster #4: Lupus anticoagulant prolongs aPTT but causes thrombosis, not bleeding—the ultimate paradox. Never let an isolated prolonged aPTT with positive lupus anticoagulant delay necessary procedures.

Approach to Isolated Thrombocytopenia

1. Confirm true thrombocytopenia (exclude pseudo-thrombocytopenia)
2. Review smear:
   • Large platelets → ITP or inherited macrothrombocytopenia
   • Schistocytes → TMA
   • Blasts → leukemia
3. Consider drug-induced (heparin-induced thrombocytopenia requires immediate cessation and alternative anticoagulation)

Pearl #7: The "4T score" risk-stratifies HIT probability (≤3 low risk, 4-5 intermediate, 6-8 high). Functional assays (serotonin release assay) are gold standard but require specialized labs.

Special Populations

Liver Disease: Complex Rebalancing

Cirrhotic patients have "rebalanced hemostasis"—simultaneous decreases in procoagulant factors AND anticoagulants. Standard tests (PT/aPTT) don't predict bleeding risk.

Hack #5: Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) better assess global hemostasis in cirrhosis than traditional tests. Many centers now use viscoelastic testing to guide transfusion.

Pearl #8: Prophylactic plasma transfusion before procedures in cirrhotic patients with elevated INR is outdated. Transfuse only for active bleeding.

Chronic Kidney Disease

Uremic platelet dysfunction causes mucous membrane bleeding despite normal platelet counts.

Treatment options:

• DDAVP 0.3 μg/kg (first-line, lasts 6-12 hours)
• Conjugated estrogens (sustained effect)
• Cryoprecipitate (rapid but blood product exposure)
• Dialysis improves platelet function

Anticoagulant-Associated Bleeding

Reversal strategies:

• Warfarin: Vitamin K (oral/IV), 4-factor PCC for urgent reversal
• Dabigatran: Idarucizumab (specific antidote)
• Xa inhibitors: Andexanet alfa (approved for apixaban/rivaroxaban)
• Unfractionated heparin: Protamine sulfate

Pearl #9: Four-factor prothrombin complex concentrate (PCC) reverses warfarin within 15 minutes versus 12-24 hours for vitamin K alone. Use for life-threatening bleeding or urgent surgery.

Emerging Concepts

COVID-19 coagulopathy: Characterized by markedly elevated D-dimer, modestly prolonged PT, and thrombotic rather than bleeding complications. Represents endothelial injury and complement activation rather than classic DIC.

Checkpoint inhibitor-associated ITP: Immune checkpoint inhibitors for cancer can trigger immune thrombocytopenia requiring corticosteroids and sometimes IVIG.

Conclusion

Distinguishing adult-onset bleeding from clotting disorders requires systematic clinical reasoning combining history, examination, and targeted laboratory testing. Internists must recognize when empiric treatment takes precedence over complete diagnosis (TTP, acquired hemophilia), understand the limitations of standard coagulation tests, and appreciate that hemostatic disorders increasingly represent complex acquired states rather than single factor deficiencies. As our population ages and therapeutic interventions expand, proficiency in hemostatic assessment becomes essential for all internal medicine practitioners.

Key References

1. Konkle BA, et al. Hemophilia A. GeneReviews. 2017 (Updated 2023).
2. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol. 2011;8(9):502-512.
3. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009;145(24-33).
4. Miyakis S, et al. International consensus statement on classification criteria for antiphospholipid syndrome. J Thromb Haemost. 2006;4(2):295-306.
5. Neunert C, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.
6. Rodeghiero F, et al. ISTH/SSC bleeding assessment tool. J Thromb Haemost. 2010;8(9):2063-2065.
7. Scully M, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2017;15(2):312-322.
8. Stevens SM, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline. Chest. 2021;160(6):e545-e608.
9. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147-156.
10. Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019;133(5):389-398.

---

Word count: ~2,000 words